Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.80 |
| ▸ | NR1I2 | O75469 | 9/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.70 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13841836 | 0.98 | KCNH2 (0.77) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL4502638 | 0.93 | KCNH2 (0.76) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL2351075 | 0.92 | KCNH2 (0.82) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL14088777 | 0.92 | KCNH2 (0.74) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL13936811 | 0.92 | KCNH2 (0.74) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL4007884 | 0.91 | KCNH2 (0.79) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL4024151 | 0.91 | KCNH2 (0.79) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL14343606 | 0.91 | KCNH2 (0.79) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL14342831 | 0.91 | NR1I2 (0.69) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL13841822 | 0.91 | NR1I2 (0.69) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008112473-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-18 | — | — | WO | disclosed |